GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Psychemedics Corp (NAS:PMD) » Definitions » Return-on-Tangible-Equity

Psychemedics (Psychemedics) Return-on-Tangible-Equity : -53.61% (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is Psychemedics Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Psychemedics's annualized net income for the quarter that ended in Dec. 2023 was $-3.78 Mil. Psychemedics's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $7.05 Mil. Therefore, Psychemedics's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was -53.61%.

The historical rank and industry rank for Psychemedics's Return-on-Tangible-Equity or its related term are showing as below:

PMD' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -47.63   Med: 10.5   Max: 48.96
Current: -47.03

During the past 13 years, Psychemedics's highest Return-on-Tangible-Equity was 48.96%. The lowest was -47.63%. And the median was 10.50%.

PMD's Return-on-Tangible-Equity is ranked worse than
70.44% of 203 companies
in the Medical Diagnostics & Research industry
Industry Median: -0.63 vs PMD: -47.03

Psychemedics Return-on-Tangible-Equity Historical Data

The historical data trend for Psychemedics's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psychemedics Return-on-Tangible-Equity Chart

Psychemedics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.67 -26.31 -5.37 -9.42 -47.63

Psychemedics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.47 -14.67 -30.10 -101.43 -53.61

Competitive Comparison of Psychemedics's Return-on-Tangible-Equity

For the Diagnostics & Research subindustry, Psychemedics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Psychemedics's Return-on-Tangible-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Psychemedics's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Psychemedics's Return-on-Tangible-Equity falls into.



Psychemedics Return-on-Tangible-Equity Calculation

Psychemedics's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-4.154/( (10.771+6.672 )/ 2 )
=-4.154/8.7215
=-47.63 %

Psychemedics's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-3.78/( (7.429+6.672)/ 2 )
=-3.78/7.0505
=-53.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Psychemedics  (NAS:PMD) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Psychemedics Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Psychemedics's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Psychemedics (Psychemedics) Business Description

Traded in Other Exchanges
N/A
Address
289 Great Road, Suite 200, Acton, MA, USA, 01720
Psychemedics Corp is engaged in providing testing services for the detection of drugs of abuse through the analysis of hair samples. The company operates through a single segment of drug testing services which include training for the collection of samples and storage of positive samples for its customers for an agreed-upon fee per unit testing of samples. The testing methods of the company utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. Geographically it generates the majority of its revenue from the United States.
Executives
Shannon Shoemaker officer: Chief Revenue Officer 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Charles M Doucot officer: Executive Vice President 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Andrew Reynolds director C/O FLEETMATICS, 1100 WINTER STREET, 4TH FL, WALTHAM MA 02451
Brian Hullinger director, officer: President & CEO 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Robyn C Davis director ONE WALLINGFORD ROAD, MARBLEHEAD MA 01945
Michael Weisenhoff other: Assistant Controller 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Michael I Schaffer officer: VP of Laboratory Operations C/O PAYCHEMEDICS CORP, 1280 MASSACHUSETTS AVE STE 200, CAMBRIDGE MA 02138
William B. Norris other: Assistant Controller 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Darius G Nevin other: See Footnote 1 C/O WCI COMMUNITIES, INC., 24301 WALDEN CENTER DRIVE, BONITA SPRINGS FL 34134
Peter H Kamin 10 percent owner 2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410
Andrew Limbek officer: Vice President & Controller 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Fred J Weinert director 330 E MAIN ST, BARRINGTON IL 60620
Kubacki Raymond C Jr director, officer: Chairman, CEO & President 125 NAGOG PARK, ACTON MA 01720
A Clinton Allen director, officer: Chairman 1280 MASSACHUSETTS AVE STE 200, CAMBRIDGE MA 02138
Neil Lerner officer: VP - Finance C/O PSYCHEMEDICS CORPORATION, 125 NAGOG PARK, ACTON MA 01720